GSK’s endometrial cancer drug to be filed later this year
admin 20th March 2019 Uncategorised 0GlaxoSmithKline group Tesaro has presented mid-stage data indicating “robust activity” of its anti-PD-1 therapy dostarlimab in patients with advanced or recurrent endometrial cancer, with a filing now on the cards for later this year.
More: GSK’s endometrial cancer drug to be filed later this year
Source: News